SG10201707633VA - Anti-egfr antibody drug conjugate formulations - Google Patents

Anti-egfr antibody drug conjugate formulations

Info

Publication number: SG10201707633VA
Authority: SG; Singapore
Prior art keywords: drug conjugate; antibody drug; egfr antibody; conjugate formulations; formulations
Prior art date: 2013-03-15

Application number

SG10201707633VA

Inventor

Markus Tschoepe

Katharina Kaleta

Vineet Kumar

Original Assignee

Abbvie Deutschland

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2017-11-29

2014-03-14 Application filed by Abbvie Deutschland, Abbvie Inc filed Critical Abbvie Deutschland

2017-11-29 Publication of SG10201707633VA publication Critical patent/SG10201707633VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Gastroenterology & Hepatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG10201707633VA 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations SG10201707633VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361790490P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
SG10201707633VA true SG10201707633VA (en)	2017-11-29

Family

ID=50680154

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201707633VA SG10201707633VA (en)	2013-03-15	2014-03-14	Anti-egfr antibody drug conjugate formulations
SG11201507430RA SG11201507430RA (en)	2013-03-15	2014-03-14	Anti-egfr antibody drug conjugate formulations

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201507430RA SG11201507430RA (en)	2013-03-15	2014-03-14	Anti-egfr antibody drug conjugate formulations

Country Status (28)

Country	Link
US (2)	US20140286969A1 (en)
EP (2)	EP2968588B1 (en)
JP (4)	JP6382935B2 (en)
KR (4)	KR20220139443A (en)
CN (2)	CN105163763B (en)
AU (4)	AU2014228172B2 (en)
BR (1)	BR112015023391A8 (en)
CA (1)	CA2906130A1 (en)
CY (1)	CY1121949T1 (en)
DK (1)	DK2968588T3 (en)
ES (1)	ES2727134T3 (en)
HK (2)	HK1217644A1 (en)
HR (1)	HRP20190672T1 (en)
HU (1)	HUE044071T2 (en)
IL (2)	IL241009A0 (en)
LT (1)	LT2968588T (en)
ME (1)	ME03457B (en)
MX (2)	MX2015012549A (en)
NZ (1)	NZ630826A (en)
PL (1)	PL2968588T3 (en)
PT (1)	PT2968588T (en)
RS (1)	RS58666B1 (en)
RU (2)	RU2015144287A (en)
SG (2)	SG10201707633VA (en)
SI (1)	SI2968588T1 (en)
TR (1)	TR201905313T4 (en)
TW (3)	TWI689313B (en)
WO (1)	WO2014143765A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9707302B2 (en) *	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
RU2013138177A (en)	2011-01-24	2015-03-10	Йм Биосайнсис Инк.	ANTIBODIES SELECTIVELY ACTING ON CELLS WITH HIGH TARGET DENSITY RECEPTOR EPIDERMAL GROWTH FACTOR (EGFR)
US20130116404A1 (en)	2011-11-08	2013-05-09	Case Western Reserve University	Targeted non-invasive imaging probes of egfr expressing cells
US11253606B2 (en)	2013-07-23	2022-02-22	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CR20210097A (en)	2014-03-21	2022-04-27	Abbvie Inc	Anti-egfr antibodies and antibody drug conjugates
KR101628872B1 (en)	2014-05-28	2016-06-09	주식회사 레고켐 바이오사이언스	Compounds comprising self-immolative group
WO2016065456A1 (en) *	2014-10-31	2016-05-06	Formation Biologics Inc.	Egfr antibody-based combination therapy
US10195175B2 (en) *	2015-06-25	2019-02-05	Immunomedics, Inc.	Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017051249A1 (en)	2015-09-25	2017-03-30	Legochem Biosciences, Inc.	Compositions and methods related to anti-cd19 antibody drug conjugates
WO2017051254A1 (en) *	2015-09-25	2017-03-30	Legochem Biosciences, Inc.	Compositions and methods related to anti-egfr antibody drug conjugates
KR20180077300A (en)	2015-11-25	2018-07-06	주식회사 레고켐 바이오사이언스	Joints comprising peptide groups and related manufacturing methods
KR20180079452A (en)	2015-11-25	2018-07-10	주식회사 레고켐 바이오사이언스	Conjugates comprising self-sacrificial groups and methods for their preparation
US11173214B2 (en)	2015-11-25	2021-11-16	Legochem Biosciences, Inc.	Antibody-drug conjugates comprising branched linkers and methods related thereto
RU2740996C2 (en) *	2016-05-17	2021-01-22	Эббви Байотерапьютикс Инк.	Conjugates of cmet antibody and drug and methods of using
EP3468616A1 (en) *	2016-06-08	2019-04-17	AbbVie Inc.	Anti-egfr antibody drug conjugates
CA3058360A1 (en)	2017-03-29	2018-10-04	Legochem Biosciences, Inc.	Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
AU2018280485A1 (en) *	2017-06-06	2020-01-30	Jiangsu Hengrui Medicine Co., Ltd.	Pharmaceutical composition comprising c-Met antibody-drug conjugate and use thereof
CN118767159A (en) *	2017-08-23	2024-10-15	第一三共株式会社	Antibody-drug conjugate formulations and lyophilization thereof
EP3677589A4 (en)	2017-08-31	2021-04-21	Daiichi Sankyo Company, Limited	Improved method for producing antibody-drug conjugate
WO2019183633A1 (en)	2018-03-23	2019-09-26	Case Western Reserve Univeristy	Psma targeted conjugate compounds and uses thereof
CN112601555A (en)	2018-05-09	2021-04-02	乐高化学生物科学股份有限公司	Compositions and methods relating to anti-CD 19 antibody drug conjugates
KR20210091698A (en) *	2018-09-20	2021-07-22	파세비오 파마수티컬스 인코포레이티드	How to reverse ticagrelor activity
CN110960490A (en) *	2018-09-28	2020-04-07	江苏恒瑞医药股份有限公司	anti-EGFR antibody coupling pharmaceutical composition and application thereof
UA128098C2 (en)	2019-02-18	2024-04-03	Елі Ліллі Енд Компані	Therapeutic antibody formulation
AU2020231509A1 (en)	2019-03-04	2021-08-19	Amgen Inc.	In vivo reversibility of high molecular weight species
WO2020192693A1 (en) *	2019-03-26	2020-10-01	荣昌生物制药(烟台)股份有限公司	Anti-her2 antibody drug conjugate pharmaceutical preparation
WO2020233534A1 (en) *	2019-05-17	2020-11-26	百奥泰生物制药股份有限公司	Antibody-drug conjugate preparation, preparation method therefor and use thereof
KR20210028544A (en)	2019-09-04	2021-03-12	주식회사 레고켐 바이오사이언스	Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
CN112516090B (en) *	2019-09-18	2023-06-20	上海复旦张江生物医药股份有限公司	Pharmaceutical composition of antibody coupled drug, freeze drying agent, preparation method and application
KR20220157998A (en) *	2020-03-25	2022-11-29	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	Pharmaceutical Compositions Comprising Antibody Drug Conjugates and Uses Thereof
US20230181499A1 (en) *	2020-04-10	2023-06-15	Lantern Pharma Inc.	Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer
KR102683876B1 (en) *	2020-11-11	2024-07-11	가톨릭대학교 산학협력단	Antibody-Based Conjugate for Enhancing Therapeutic Effect of Targeted Therapeutics
EP4245319A1 (en) *	2020-11-11	2023-09-20	The Catholic University of Korea Industry-Academic Cooperation Foundation	Antibody-based conjugate for enhancing therapeutic effect of targeted therapeutic agent
AR124414A1 (en)	2020-12-18	2023-03-22	Century Therapeutics Inc	CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY
AR124681A1 (en)	2021-01-20	2023-04-26	Abbvie Inc	ANTI-EGFR ANTIBODY-DRUG CONJUGATES
CN115300623B (en) *	2021-05-08	2024-06-21	盛禾(中国)生物制药有限公司	Compositions of anti-EGFR fusion proteins or antigen binding fragments thereof and uses thereof
US20230027739A1 (en)	2021-05-10	2023-01-26	Entrada Therapeutics, Inc.	Antigen-binding and antigen degradation constructs
CN115721732A (en) *	2021-08-27	2023-03-03	上海复旦张江生物医药股份有限公司	Pharmaceutical composition and preparation of antibody-conjugated drug, preparation method and application thereof
EP4429654A1 (en)	2021-11-09	2024-09-18	Case Western Reserve University	Psma targeted conjugate compounds and uses thereof
CN114740108B (en) *	2022-03-28	2023-07-14	天津键凯科技有限公司	Method for measuring modification degree of polymer modified antibody drug
WO2023240223A2 (en) *	2022-06-10	2023-12-14	Acelyrin, Inc.	Anti-igf-1r antibody compositions
TW202412856A (en) *	2022-06-15	2024-04-01	大陸商上海翰森生物醫藥科技有限公司	Pharmaceutical composition containing an antibody drug conjugate and use thereof
EP4353220A1 (en) *	2022-10-12	2024-04-17	Pierre Fabre Medicament	Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4563304A (en)	1981-02-27	1986-01-07	Pharmacia Fine Chemicals Ab	Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4486414A (en)	1983-03-21	1984-12-04	Arizona Board Of Reagents	Dolastatins A and B cell growth inhibitory substances
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US4816444A (en)	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
DE68921982D1 (en)	1988-06-14	1995-05-04	Cetus Oncology Corp	COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
EP0768377A1 (en)	1988-09-02	1997-04-16	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5076973A (en)	1988-10-24	1991-12-31	Arizona Board Of Regents	Synthesis of dolastatin 3
US5750373A (en)	1990-12-03	1998-05-12	Genentech, Inc.	Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR0184860B1 (en)	1988-11-11	1999-04-01	메디칼 리써어치 카운실	Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US4978744A (en)	1989-01-27	1990-12-18	Arizona Board Of Regents	Synthesis of dolastatin 10
US4879278A (en)	1989-05-16	1989-11-07	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en)	1989-05-18	1991-01-22	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en)	1989-11-13	1992-08-11	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
WO1992018619A1 (en)	1991-04-10	1992-10-29	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
JPH07503124A (en)	1991-06-14	1995-04-06	ゾーマ・コーポレーション	Antibody fragments and their complexes produced by microorganisms
ES2227512T3 (en)	1991-12-02	2005-04-01	Medical Research Council	PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US6034065A (en)	1992-12-03	2000-03-07	Arizona Board Of Regents	Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en)	1993-01-21	1995-04-25	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
US5556623A (en)	1993-03-30	1996-09-17	Eli Lilly And Company	Antibody-drug conjugates
US6214345B1 (en)	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
JPH09506262A (en)	1993-12-08	1997-06-24	ジェンザイム・コーポレイション	Method for producing specific antibody
ES2166368T3 (en) *	1993-12-24	2002-04-16	Merck Patent Gmbh	IMMUNOCONJUGADOS.
DK0744958T3 (en)	1994-01-31	2003-10-20	Univ Boston	Polyclonal antibody libraries
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5504191A (en)	1994-08-01	1996-04-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide methyl esters
US5530097A (en)	1994-08-01	1996-06-25	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory peptide amides
US5521284A (en)	1994-08-01	1996-05-28	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide amides and esters
US5554725A (en)	1994-09-14	1996-09-10	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Synthesis of dolastatin 15
US5599902A (en)	1994-11-10	1997-02-04	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Cancer inhibitory peptides
US5663149A (en)	1994-12-13	1997-09-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JP2978435B2 (en)	1996-01-24	1999-11-15	チッソ株式会社	Method for producing acryloxypropyl silane
EP0973540B1 (en)	1997-02-25	2005-11-02	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en)	1999-09-10	2001-11-27	Basf Aktiengesellschaft	Dolastatin peptides
US20040018194A1 (en)	2000-11-28	2004-01-29	Francisco Joseph A.	Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en)	2000-11-28	2006-08-15	Seattle Genetics, Inc.	Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en)	2000-11-28	2007-11-08	Seattle Genetics, Inc.	Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1243276A1 (en)	2001-03-23	2002-09-25	Franciscus Marinus Hendrikus De Groot	Elongated and multiple spacers containing activatible prodrugs
US7256257B2 (en)	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US20030083263A1 (en)	2001-04-30	2003-05-01	Svetlana Doronina	Pentapeptide compounds and uses related thereto
US6884869B2 (en)	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US7091186B2 (en)	2001-09-24	2006-08-15	Seattle Genetics, Inc.	p-Amidobenzylethers in drug delivery agents
US20090068178A1 (en) *	2002-05-08	2009-03-12	Genentech, Inc.	Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP1545613B9 (en)	2002-07-31	2012-01-25	Seattle Genetics, Inc.	Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003282624A1 (en)	2002-11-14	2004-06-03	Syntarga B.V.	Prodrugs built as multiple self-elimination-release spacers
US20050023292A1 (en) *	2003-02-14	2005-02-03	Rubbermaid Commercial Products Llc	Liquid dispenser
ES2605443T3 (en)	2003-11-06	2017-03-14	Seattle Genetics, Inc.	Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP1725586B1 (en)	2004-03-02	2015-01-14	Seattle Genetics, Inc.	Partially loaded antibodies and methods of their conjugation
EP1740954B1 (en) *	2004-04-07	2015-08-19	Genentech, Inc.	Mass spectrometry of antibody conjugates
EP3088004B1 (en) *	2004-09-23	2018-03-28	Genentech, Inc.	Cysteine engineered antibodies and conjugates
CA2616005C (en)	2005-07-18	2015-09-22	Seattle Genetics, Inc.	Beta-glucuronide-linker drug conjugates
JP2009509918A (en)	2005-08-05	2009-03-12	シンタルガ・ビーブイ	Triazole-containing releasable linkers, their conjugates, and production methods
US8586714B2 (en) *	2009-09-01	2013-11-19	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
US20110076232A1 (en) *	2009-09-29	2011-03-31	Ludwig Institute For Cancer Research	Specific binding proteins and uses thereof
CN102892430A (en) *	2010-03-17	2013-01-23	雅培研究有限公司	Anti-nerve growth factor (ngf) antibody compositions
US9044460B2 (en) *	2010-05-04	2015-06-02	Merrimack Pharmaceuticals, Inc.	Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
UA116189C2 (en) *	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	FORMULATION FOR ANTI-α4β7 ANTIBODY
SG10201800313UA (en) *	2013-03-15	2018-02-27	Abbvie Inc	Antibody drug conjugate (adc) purification
MY182415A (en) *	2014-02-18	2021-01-25	Illumina Inc	Methods and compositions for dna profiling

2014
- 2014-03-14 SG SG10201707633VA patent/SG10201707633VA/en unknown
- 2014-03-14 CN CN201480025078.7A patent/CN105163763B/en active Active
- 2014-03-14 RS RS20190452A patent/RS58666B1/en unknown
- 2014-03-14 TR TR2019/05313T patent/TR201905313T4/en unknown
- 2014-03-14 KR KR1020227034264A patent/KR20220139443A/en active Application Filing
- 2014-03-14 PL PL14722450T patent/PL2968588T3/en unknown
- 2014-03-14 MX MX2015012549A patent/MX2015012549A/en active IP Right Grant
- 2014-03-14 WO PCT/US2014/027868 patent/WO2014143765A1/en active Application Filing
- 2014-03-14 KR KR1020157029907A patent/KR102305226B1/en active IP Right Grant
- 2014-03-14 AU AU2014228172A patent/AU2014228172B2/en not_active Ceased
- 2014-03-14 RU RU2015144287A patent/RU2015144287A/en not_active Application Discontinuation
- 2014-03-14 TW TW103109817A patent/TWI689313B/en active
- 2014-03-14 NZ NZ630826A patent/NZ630826A/en not_active IP Right Cessation
- 2014-03-14 TW TW108107373A patent/TW201945032A/en unknown
- 2014-03-14 SI SI201431167T patent/SI2968588T1/en unknown
- 2014-03-14 KR KR1020227009445A patent/KR20220041957A/en not_active Application Discontinuation
- 2014-03-14 US US14/211,954 patent/US20140286969A1/en not_active Abandoned
- 2014-03-14 CN CN201910492831.8A patent/CN110433139A/en active Pending
- 2014-03-14 HU HUE14722450A patent/HUE044071T2/en unknown
- 2014-03-14 JP JP2016502649A patent/JP6382935B2/en not_active Expired - Fee Related
- 2014-03-14 EP EP14722450.5A patent/EP2968588B1/en active Active
- 2014-03-14 ME MEP-2019-102A patent/ME03457B/en unknown
- 2014-03-14 DK DK14722450.5T patent/DK2968588T3/en active
- 2014-03-14 RU RU2020125266A patent/RU2020125266A/en unknown
- 2014-03-14 KR KR1020217029935A patent/KR20210118238A/en active Application Filing
- 2014-03-14 ES ES14722450T patent/ES2727134T3/en active Active
- 2014-03-14 TW TW110106528A patent/TW202146054A/en unknown
- 2014-03-14 LT LTEP14722450.5T patent/LT2968588T/en unknown
- 2014-03-14 BR BR112015023391A patent/BR112015023391A8/en active Search and Examination
- 2014-03-14 CA CA2906130A patent/CA2906130A1/en not_active Abandoned
- 2014-03-14 SG SG11201507430RA patent/SG11201507430RA/en unknown
- 2014-03-14 PT PT14722450T patent/PT2968588T/en unknown
- 2014-03-14 EP EP18211172.4A patent/EP3517132A1/en not_active Withdrawn
2015
- 2015-09-01 IL IL241009A patent/IL241009A0/en unknown
- 2015-09-11 MX MX2020000333A patent/MX2020000333A/en unknown
2016
- 2016-05-16 HK HK16105609.4A patent/HK1217644A1/en not_active IP Right Cessation
- 2016-06-13 HK HK16106793.8A patent/HK1219044A1/en unknown
2018
- 2018-08-02 JP JP2018145641A patent/JP2018184468A/en active Pending
- 2018-11-23 AU AU2018267662A patent/AU2018267662A1/en not_active Abandoned
2019
- 2019-04-09 HR HRP20190672TT patent/HRP20190672T1/en unknown
- 2019-04-09 CY CY20191100397T patent/CY1121949T1/en unknown
- 2019-10-17 US US16/655,716 patent/US20200282072A1/en not_active Abandoned
2020
- 2020-05-24 IL IL274881A patent/IL274881A/en unknown
- 2020-06-03 JP JP2020096643A patent/JP2020143152A/en active Pending
- 2020-11-25 AU AU2020277164A patent/AU2020277164A1/en not_active Abandoned
2022
- 2022-06-20 JP JP2022098605A patent/JP2022126754A/en active Pending
2023
- 2023-01-27 AU AU2023200432A patent/AU2023200432A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2014228172A1 (en)	2015-09-24
HUE044071T2 (en)	2019-09-30
JP2022126754A (en)	2022-08-30
JP2020143152A (en)	2020-09-10
US20140286969A1 (en)	2014-09-25
TR201905313T4 (en)	2019-05-21
EP2968588B1 (en)	2019-01-09
CN110433139A (en)	2019-11-12
RU2015144287A3 (en)	2018-03-19
ES2727134T3 (en)	2019-10-14
AU2020277164A1 (en)	2020-12-24
MX2015012549A (en)	2016-06-21
ME03457B (en)	2020-01-20
PT2968588T (en)	2019-05-08
LT2968588T (en)	2019-05-10
JP2016515511A (en)	2016-05-30
AU2018267662A1 (en)	2018-12-13
KR102305226B1 (en)	2021-09-29
SI2968588T1 (en)	2019-05-31
NZ732015A (en)	2022-01-28
BR112015023391A2 (en)	2017-11-28
EP3517132A1 (en)	2019-07-31
DK2968588T3 (en)	2019-04-23
NZ630826A (en)	2017-06-30
WO2014143765A8 (en)	2015-09-11
US20200282072A1 (en)	2020-09-10
KR20220139443A (en)	2022-10-14
TWI689313B (en)	2020-04-01
KR20150131366A (en)	2015-11-24
KR20210118238A (en)	2021-09-29
TW201519903A (en)	2015-06-01
JP6382935B2 (en)	2018-08-29
TW201945032A (en)	2019-12-01
PL2968588T3 (en)	2019-08-30
TW202146054A (en)	2021-12-16
AU2014228172B2 (en)	2018-12-06
EP2968588A1 (en)	2016-01-20
SG11201507430RA (en)	2015-10-29
CN105163763B (en)	2019-07-02
RU2020125266A (en)	2020-09-24
JP2018184468A (en)	2018-11-22
IL241009A0 (en)	2015-11-30
IL274881A (en)	2020-07-30
MX2020000333A (en)	2020-07-13
CN105163763A (en)	2015-12-16
BR112015023391A8 (en)	2018-01-30
HRP20190672T1 (en)	2019-08-23
HK1219044A1 (en)	2017-03-24
RS58666B1 (en)	2019-06-28
CA2906130A1 (en)	2014-09-18
AU2023200432A1 (en)	2023-03-02
RU2015144287A (en)	2017-04-24
KR20220041957A (en)	2022-04-01
WO2014143765A1 (en)	2014-09-18
CY1121949T1 (en)	2020-10-14
HK1217644A1 (en)	2017-01-20

Publication	Publication Date	Title
IL274881A (en)	2020-07-30	Anti-egfr antibody drug conjugate formulations
IL291073A (en)	2022-05-01	Anti-egfr antibody drug conjugates
HK1210477A1 (en)	2016-04-22	Antibody drug conjugate
IL241277A0 (en)	2015-11-30	Antibody drug conjugates
EP2982681B8 (en)	2018-11-07	Wt1-antigen peptide conjugate vaccine
ZA201508487B (en)	2017-11-29	Antibody drug conjugates
EP2968600A4 (en)	2017-03-08	Antibody drug conjugates
IL252441A0 (en)	2017-08-31	C-met antibody drug conjugate
SG11201509194SA (en)	2015-12-30	Radiomitigating pharmaceutical formulations
SG11201506358PA (en)	2015-09-29	Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
ZA201600027B (en)	2018-07-25	Pharmaceutical preparation
ZA201506465B (en)	2021-06-30	Pharmaceutical preparation